CD42B抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD42B mouse mAb against K562 (1), HL-60 (2), and Ramos (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD42B mouse mAb (green) and negative control (red).    

  
  

CD42B, also known as glycoprotein Ibα (GPIbα), is a key platelet surface receptor component of the GPIb-IX-V complex, which plays a critical role in primary hemostasis and thrombosis. The CD42B antibody specifically targets the GPIbα subunit, a 140-kDa transmembrane protein encoded by the GP1BA gene. This receptor mediates platelet adhesion to von Willebrand factor (VWF) at sites of vascular injury under high shear stress, initiating platelet activation and aggregation.

CD42B antibodies are widely used in research and diagnostics to study platelet function and quantify GPIbα expression. In clinical settings, they aid in diagnosing inherited platelet disorders like Bernard-Soulier syndrome (BPS), characterized by GPIb-IX-V deficiency. Monoclonal CD42B antibodies (e.g., clone SZ2) are employed in flow cytometry to identify platelet populations, assess activation states, or detect autoantibodies in immune thrombocytopenia (ITP).

Additionally, CD42B antibodies have therapeutic implications. Some inhibit GPIbα-VWF interactions to prevent pathological thrombosis, while others are explored for targeting platelets in inflammation or cancer metastasis. Challenges include balancing hemostatic safety in antithrombotic therapies. Overall, CD42B antibodies remain vital tools for understanding platelet biology and advancing hematologic disease management.